BPIFA2

Across TCGA pan-cancer cohorts, BPIFA2 mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated BPIFA2 data layer compared with 20 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher BPIFA2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated BPIFA2 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

HNSC are the cancer types where BPIFA2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Tertile	III,IV	1.000	0.380	.013	12	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

BPIFA2–HNSC (DFS)

Open the HNSC breakdown →